AU8723691A - Natural killer stimulatory factor - Google Patents

Natural killer stimulatory factor

Info

Publication number
AU8723691A
AU8723691A AU87236/91A AU8723691A AU8723691A AU 8723691 A AU8723691 A AU 8723691A AU 87236/91 A AU87236/91 A AU 87236/91A AU 8723691 A AU8723691 A AU 8723691A AU 8723691 A AU8723691 A AU 8723691A
Authority
AU
Australia
Prior art keywords
natural killer
stimulatory factor
killer stimulatory
factor
natural
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU87236/91A
Other languages
English (en)
Inventor
Steven C. Clark
Rodney Hewick
Michiko Kobayashi
Bice Perussia
Giorgio Trinchieri
Gordon G. Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
The Wistar Institute
Original Assignee
Genetics Institute LLC
The Wistar Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute LLC, The Wistar Institute filed Critical Genetics Institute LLC
Publication of AU8723691A publication Critical patent/AU8723691A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/803—Physical recovery methods, e.g. chromatography, grinding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU87236/91A 1990-09-18 1991-09-04 Natural killer stimulatory factor Abandoned AU8723691A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/584,941 US5457038A (en) 1988-11-10 1990-09-18 Natural killer stimulatory factor
US584941 1990-09-18

Publications (1)

Publication Number Publication Date
AU8723691A true AU8723691A (en) 1992-04-15

Family

ID=24339390

Family Applications (1)

Application Number Title Priority Date Filing Date
AU87236/91A Abandoned AU8723691A (en) 1990-09-18 1991-09-04 Natural killer stimulatory factor

Country Status (5)

Country Link
US (4) US5457038A (enExample)
EP (1) EP0549711A1 (enExample)
JP (3) JP4014590B2 (enExample)
AU (1) AU8723691A (enExample)
WO (1) WO1992005256A1 (enExample)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150328A (en) * 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
US5811523A (en) 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US5780597A (en) * 1989-12-22 1998-07-14 Hoffmann-La Roche Inc. Monoclonal antibodies to cytotoxic lymphocyte maturation factor
DK0433827T3 (da) * 1989-12-22 1998-09-28 Hoffmann La Roche Cytotoksisk lumfocytmodningsfaktor
US20080070842A1 (en) * 1991-11-04 2008-03-20 David Israel Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
KR100259827B1 (ko) 1991-11-04 2000-06-15 브루스 엠. 에이센, 토마스 제이 데스로저 재조합 골형태 형성 단백질 헤테로다이머, 그 조성물 및 사용방법
US6399379B1 (en) 1992-09-29 2002-06-04 Isis Pharmaceuticals, Inc. Antisense modulation of interleukin 12 p35 subunit expression
CA2125763C (en) * 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
EP0733109B9 (en) * 1993-12-07 2006-07-05 Genetics Institute, LLC Bmp-12, bmp-13 and tendon-inducing compositions thereof
US6706264B1 (en) 1994-03-14 2004-03-16 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US5635182A (en) * 1994-06-16 1997-06-03 Genetics Institute, Inc. Method of detecting ligand interactions
DE69519454T2 (de) 1994-07-14 2001-05-03 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama Protein, das Interferon-Gamma Herstellung induziert und monoklonaler Antikörper dagegen
TW581771B (en) * 1994-11-15 2004-04-01 Hayashibara Biochem Lab Recombinant production of a polypeptide for inducing interferon-gamma production, and monoclonal antibody against the polypeptide
JP2724987B2 (ja) 1994-11-15 1998-03-09 株式会社林原生物化学研究所 インターフェロン−γの産生を誘導するポリペプチド
JP4004088B2 (ja) 1995-09-26 2007-11-07 株式会社林原生物化学研究所 免疫担当細胞においてインターフェロン−γの産生を誘導する蛋白質
US7135458B1 (en) 1995-11-15 2006-11-14 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interferon-γ inducing polypeptide, pharmaceutical composition thereof, monoclonal antibody thereto, and methods of use
US5674483A (en) * 1995-01-31 1997-10-07 National Jewish Medical And Research Center Treatment for diseases involving inflammation
JP2000510813A (ja) * 1995-02-06 2000-08-22 ジェネテイックス・インスティテュート・インコーポレイテッド Ｉｌ−１２用処方
US5891680A (en) * 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
US6372208B1 (en) 1999-09-28 2002-04-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant virus
US6251957B1 (en) 1995-02-24 2001-06-26 Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant virus
US5853714A (en) * 1995-03-27 1998-12-29 Genetics Institute, Inc. Method for purification of IL-12
US6509313B1 (en) * 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
GB9609932D0 (en) * 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
EP0931156A2 (en) * 1996-10-18 1999-07-28 Valentis Inc. Gene expression and delivery systems and uses
WO1998017689A2 (en) * 1996-10-18 1998-04-30 Valentis Inc. Il-12 gene expression and delivery systems and uses
CA2745736C (en) * 1996-10-23 2016-11-22 The Trustees Of The University Of Pennsylvania Immunotherapy and improved vaccines
US5994104A (en) * 1996-11-08 1999-11-30 Royal Free Hospital School Of Medicine Interleukin-12 fusion protein
WO1998041229A1 (en) * 1997-03-19 1998-09-24 F. Hoffmann-La Roche Ag USE OF IL-12p40 AS IMMUNOSTIMULANT
EP1030681A4 (en) * 1997-11-03 2001-07-04 Wistar Inst METHOD AND COMPOSITIONS FOR INHIBITING ANGIOGENESIS AND TREATING CANCER
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
DE69916022T2 (de) * 1998-01-23 2004-09-02 Genetics Institute, LLC, Cambridge Methode zur Verwendung von IL-11 zur Verstärkung der zellvermittelten Immunität zur Behandlung verschiedener viraler und parasitärer Infektionen und Krebs
US7026456B1 (en) 1998-01-23 2006-04-11 Hoffman-La Roche, Inc. Antibodies against human IL-12
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
US7247442B1 (en) 1998-05-12 2007-07-24 Human Genome Sciences, Inc. Antibodies to HHPEN62 polypeptide
US6375944B1 (en) 1998-09-25 2002-04-23 The Wistar Institute Of Anatomy And Biology Methods and compositions for enhancing the immunostimulatory effect of interleukin-12
US6448081B1 (en) * 2001-05-07 2002-09-10 Isis Pharmaceuticals, Inc. Antisense modulation of interleukin 12 p40 subunit expression
US6727224B1 (en) * 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
US6570002B1 (en) * 1999-02-26 2003-05-27 The Johns Hopkins University Inhibitor of programmed cell death
US6800460B1 (en) 1999-03-11 2004-10-05 Schering Corporation Mammalian cytokine complexes
JP2003508013A (ja) * 1999-03-12 2003-03-04 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ５０個のヒト分泌タンパク質
AU3517000A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. 50 human secreted proteins
WO2000061628A1 (en) * 1999-04-09 2000-10-19 Human Genome Sciences, Inc. 49 human secreted proteins
WO2000055201A1 (en) * 1999-03-12 2000-09-21 Human Genome Sciences, Inc. 49 human secreted proteins
AU3767000A (en) * 1999-03-26 2000-10-16 Human Genome Sciences, Inc. 50 human secreted proteins
EP1171462A2 (en) * 1999-03-26 2002-01-16 Human Genome Sciences, Inc. 49 human secreted proteins
AU4066800A (en) * 1999-04-01 2000-10-23 Genetics Institute Inc. Angiopoietin-like proteins, crisp proteins and polynucleotides encoding same
EP1203018A1 (en) * 1999-07-21 2002-05-08 Human Genome Sciences, Inc. 26 human prostate and prostate cancer associated proteins
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2001010912A1 (en) 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
JP2003507036A (ja) * 1999-08-16 2003-02-25 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド レチノイドレセプター相互作用ポリヌクレオチド、ポリペプチド、および抗体
JP2003533968A (ja) * 1999-09-03 2003-11-18 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 免疫グロブリンスーパーファミリーポリヌクレオチド、ポリペプチド、および抗体
CA2384672A1 (en) * 1999-09-09 2001-03-15 Human Genome Sciences, Inc. Steroid hormone receptor polynucleotides, polypeptides, and antibodies
AU7603800A (en) * 1999-09-24 2001-04-24 Human Genome Sciences, Inc. 32 human secreted proteins
EP1223990B1 (en) 1999-10-15 2004-07-28 Genetics Institute, LLC Formulations of hyaluronic acid for delivery of osteogenic proteins
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
US7115712B1 (en) * 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
EP1248801A4 (en) * 2000-01-18 2003-08-27 Human Genome Sciences Inc HUMANE POLYNUCLEOTIDES, POLYPEPTIDES AND ANTIBODIES
WO2001055448A1 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
AU2001238585A1 (en) * 2000-02-24 2001-09-03 Human Genome Sciences, Inc. Human polynucleotides, polypeptides, and antibodies
WO2001070804A1 (en) * 2000-03-17 2001-09-27 Human Genome Sciences, Inc. 7 human ovarian and ovarian cancer associated proteins
US20030166044A1 (en) * 2000-03-31 2003-09-04 Kenneth Jacobs Novel proteins
CA2404074A1 (en) * 2000-04-03 2001-10-11 Human Genome Sciences, Inc. Human polynucleotides, polypeptides, and antibodies
AU2001253362A1 (en) * 2000-04-13 2001-10-30 Smith Kline Beecham Corporation Novel compounds
NZ523122A (en) * 2000-06-22 2004-06-25 Smithkline Beecham Corp Polypeptides and polynucleotides and methods of identifying agonists and antagonists in relation to treatment of diseases
CZ2003214A3 (cs) * 2000-06-29 2003-08-13 Merck Patent Gmbh Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu
US6902734B2 (en) * 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
EP1313761A4 (en) * 2000-08-28 2005-01-26 Human Genome Sciences Inc 18 HUMAN, SPECIFIC PROTEINS
US20030082233A1 (en) * 2000-12-01 2003-05-01 Lyons Karen M. Method and composition for modulating bone growth
DK1366067T3 (da) 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
BR0209177A (pt) 2001-05-03 2004-10-05 Merck Patent Gmbh Anticorpo especìfico a tumor recombinante e uso do mesmo
US7226587B2 (en) * 2001-06-01 2007-06-05 Wyeth Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
TWI267378B (en) * 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
EP1454138B1 (en) 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
ATE471946T1 (de) 2002-12-17 2010-07-15 Merck Patent Gmbh Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
US7939058B2 (en) 2003-07-03 2011-05-10 University Of Southern California Uses of IL-12 in hematopoiesis
TW200518767A (en) * 2003-09-12 2005-06-16 Wyeth Corp Injectable calcium phosphate solid rods and pastes for delivery of osteogenic proteins
CA2552590A1 (en) * 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
US20040260068A1 (en) * 2004-02-26 2004-12-23 Naoya Tsurushita Humanized chicken antibodies
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
CA2591813A1 (en) 2004-12-21 2006-06-29 Centocor, Inc. Anti-il-12 antibodies, epitopes, compositions, methods and uses
US20060166251A1 (en) * 2005-01-26 2006-07-27 Archambault Joanne M Use of sFRPs as markers of BMP activity
JP2008534607A (ja) * 2005-03-30 2008-08-28 ワイス Ｂｍｐを投与することによって毛髪の成長を刺激するための方法
SI1966238T1 (sl) * 2005-12-30 2012-08-31 Merck Patent Gmbh Variante interlevkina-12P40 z izboljšano stabilnostjo
WO2008070647A1 (en) * 2006-12-07 2008-06-12 Wyeth Methods and compositions for assessing il-12 or the neutralization of il-12 in a sample
EP2248903A1 (en) 2009-04-29 2010-11-10 Universitat Autònoma De Barcelona Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
EP2571516B1 (en) 2010-05-18 2017-11-15 Neumedicines, Inc Il-12 formulations for enhancing hematopoiesis
WO2012174056A1 (en) 2011-06-13 2012-12-20 Neumedicines, Inc. Mitigation of cutaneous injury with il-12
EP2736530B1 (en) 2011-07-27 2018-06-06 Neumedicines, Inc Use of il-12 to generate endogenous erythropoietin
US9636381B2 (en) 2012-01-18 2017-05-02 Neumedicines, Inc. Methods for radiation protection by administering IL-12
US20140350087A9 (en) 2012-03-22 2014-11-27 Halozyme, Inc. Oncovector Nucleic Acid Molecules and Methods of Use
EP2940128A1 (en) 2014-04-30 2015-11-04 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Adenovirus comprising an albumin-binding moiety
AU2016334401A1 (en) 2015-10-10 2018-04-26 Intrexon Corporation Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
EP3436477A2 (en) 2016-03-29 2019-02-06 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12 and/or -23 antibody
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
WO2019220412A2 (en) 2018-05-18 2019-11-21 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-il12/il23 antibody
HUE063462T2 (hu) 2018-09-24 2024-01-28 Janssen Biotech Inc A colitis ulcerosa kezelésének biztonságos és hatékony eljárása anti-IL12/IL23 antitesttel
EP3972690A4 (en) 2019-05-23 2023-07-05 Janssen Biotech, Inc. METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF-ALPHA
CA3183927A1 (en) 2020-05-21 2021-11-25 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
IL312221A (en) 2021-10-20 2024-06-01 Synthekine Inc Heterodimeric fc cytokines and uses thereof
WO2023070038A2 (en) * 2021-10-20 2023-04-27 Synthekine, Inc. Human il-12p40 variants and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4473555A (en) * 1983-10-17 1984-09-25 Syntex (U.S.A.) Inc. Nona- and dodecapeptides for augmenting natural killer cell activity
US4879111A (en) * 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
US5185431A (en) * 1988-08-31 1993-02-09 Eisai Co., Ltd. Recombinant natural killer cell activator
WO1990005147A1 (en) * 1988-11-10 1990-05-17 Genetics Institute, Inc. Natural killer stimulatory factor
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
DK0433827T3 (da) * 1989-12-22 1998-09-28 Hoffmann La Roche Cytotoksisk lumfocytmodningsfaktor

Also Published As

Publication number Publication date
JP3652365B2 (ja) 2005-05-25
US5457038A (en) 1995-10-10
WO1992005256A1 (en) 1992-04-02
US5648072A (en) 1997-07-15
JP2005046158A (ja) 2005-02-24
JPH06501009A (ja) 1994-01-27
JP4423313B2 (ja) 2010-03-03
US5648467A (en) 1997-07-15
EP0549711A1 (en) 1993-07-07
JP2009178164A (ja) 2009-08-13
JP4014590B2 (ja) 2007-11-28
JP2007306929A (ja) 2007-11-29
US5569454A (en) 1996-10-29

Similar Documents

Publication Publication Date Title
AU639126B2 (en) Oxorapamycin
AU6018194A (en) Easy intubator
AU4677089A (en) Chair
AU8690791A (en) Replacing mains
HK1008072B (en) Replacing mains
AU8405691A (en) Novel tetrahydrobenzazole derivative
AU6907891A (en) Pocket-spring mattress
AU8028791A (en) Height-controllable chair
AU7804691A (en) N-pyridinesulfonyl-N-pyrimidinyl-or-triazinylureas
AU7956191A (en) Transportsystem
AU9030991A (en) Improved capacitor-sensor
AU7726391A (en) Slitterscorer
AU639075B2 (en) Governor
AU2010992A (en) Novel azabicyclobenzisoquinolines
AU6531090A (en) Swagable fitting
AU603757B3 (en) Lighting unit
AU7587991A (en) Electrodermatome
AU7446891A (en) Aquaculture
AU7752291A (en) Stay
AU8516291A (en) Instant photograph-postcard
AU7976491A (en) Special effects controller
AU7922191A (en) 2-acylamino-7-chlorobenzothiazoles
AU8394391A (en) Fuel pumping apparatus
AU620759B2 (en) Improvements relating to natural lighting techniques
AU5711090A (en) Trailer-barrow